Mazdutide 10mg 10vials

Description

Mazdutide Dual GLP-1/GCGR Agonist for Weight Loss Research

How It Works

The biochemical activity of Mazdutide is defined by its ability to engage two distinct GPCR pathways to modulate systemic energy balance. The primary mechanism involves the peptide binds to the GLP-1 receptor, initiating the adenylyl cyclase cascade in pancreatic and hypothalamic cells. This defines the first semantic triple: [Mazdutide stimulates GLP-1R signaling]. Additionally, the molecule functions as a potent agonist at the glucagon receptor (GCGR), promoting hepatic gluconeogenesis and thermogenesis in adipose tissue. This establishes the second triple: [Glucagon receptor activation increases thermogenesis]. Furthermore, this dual agonism creates a metabolic environment that enhances lipid oxidation while suppressing caloric intake through centrally mediated satiety. This forms the third triple: [Dual agonism modulates hepatic glucose output]. Quantitatively, Mazdutide demonstrates a systemic half-life of approximately 150 hours, facilitating a sustained research model. Unlike Semaglutide, which relies solely on incretin-based pathways, Mazdutide incorporates the catabolic signaling of glucagon to potentially increase the basal metabolic rate.

Product Profile

Mazdutide is a synthetic, long-acting oxyntomodulin analog designed to achieve metabolic homeostasis through the concurrent activation of the glucagon-like peptide-1 receptor and the glucagon receptor. This signaling molecule serves as a premier research tool for investigating the synergistic effects of dual-receptor saturation on energy expenditure and appetite regulation.

Specification Sheet

• CAS Number: 2420653-38-1
• Molecular Formula: C218H340N56O68S (Approximate)
• Molecular Weight: ~4842.5 Da
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

Known Effects

• Enhanced Satiety Modulation: Study findings show a profound reduction in appetite through the inhibition of gastric motility and hypothalamic signaling.
• Optimized Metabolic Rate: Experimental findings suggest increased resting energy expenditure in research models of metabolic syndrome.
• Substantial Adipose Remodeling: According to research documentation, research models show accelerated loss of visceral fat mass via enhanced fatty acid oxidation.
• Improved Glycemic Resilience: Cumulative findings indicate stabilized postprandial glucose levels and improved insulin sensitivity.
• Liver Lipid Regulation: Research models demonstrate a marked reduction in intrahepatic lipid accumulation during chronic administration phases.

In Brief:
Mazdutide represents a high-feasibility research tool for investigating the intersection of incretin and glucagon signaling in the regulation of systemic metabolism.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.